Punch & Associates Investment Management Inc. Buys Shares of 834,750 InfuSystem Holdings, Inc. $INFU

Key Points

• Punch & Associates purchased 834,750 shares of InfuSystem, valued at approximately $8.1 million, giving it a 4.14% stake. Institutional investors collectively own 71.13% of the company.
• InfuSystem authorized a $20 million stock repurchase program, allowing it to buy back up to 10.2% of outstanding shares.
• Analysts maintain a favorable outlook, with three Buy ratings and one Hold rating, an average price target of $16.67, and B. Riley raising its target to $20 from $12.

Punch & Associates Investment Management Inc. bought a new position in InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 834,750 shares of the company's stock, valued at approximately $8,055,000. Punch & Associates Investment Management Inc. owned 4.14% of InfuSystem at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Meros Investment Management LP purchased a new position in shares of InfuSystem in the 2nd quarter valued at $4,525,213,000. Heartland Advisors Inc. purchased a new stake in shares of InfuSystem during the 2nd quarter worth $6,755,000. GSA Capital Partners LLP purchased a new stake in shares of InfuSystem during the 2nd quarter worth $1,548,000. Diamond Hill Capital Management LLC Investment Advisor bought a new stake in InfuSystem during the second quarter valued at about $4,719,000. Finally, Expect Equity LLC bought a new stake in InfuSystem during the second quarter valued at about $1,784,000. Institutional investors own 71.13% of the company's stock.

InfuSystem Price Performance

NYSE INFU opened at $12.04 on Thursday. The firm's fifty day simple moving average is $10.37 and its two-hundred day simple moving average is $9.62. The firm has a market capitalization of $242.99 million, a P/E ratio of 200.70 and a beta of 1.42. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. InfuSystem Holdings, Inc. has a 12-month low of $7.29 and a 12-month high of $12.97.

InfuSystem announced that its Board of Directors has authorized a stock repurchase program on Tuesday, May 19th that allows the company to repurchase $20.00 million in shares. This repurchase authorization allows the company to reacquire up to 10.2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board believes its shares are undervalued.

Wall Street Analyst Weigh In

Separately, B. Riley Financial reiterated a "buy" rating and issued a $20.00 target price (up from $12.00) on shares of InfuSystem in a report on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $16.67.

InfuSystem Profile

InfuSystem Holdings Inc is a medical technology company that specializes in the rental, management and servicing of infusion pumps and associated devices used primarily for outpatient infusion therapy. The company provides a comprehensive suite of services that includes equipment delivery, setup and retrieval, preventive and corrective maintenance, reprocessing and quality assurance. InfuSystem's offerings are designed to help hospitals, ambulatory surgery centers, oncology clinics and private infusion suites streamline clinical operations and maintain compliance with safety standards.

In addition to pump rental and repair services, InfuSystem has expanded into remote patient monitoring solutions.

Want to see what other hedge funds are holding INFU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InfuSystem Holdings, Inc. (NYSE:INFU - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.